# RYTM catalysts: RHYTHM PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rytm/catalysts

> RHYTHM PHARMACEUTICALS, INC. (RYTM) has 4 upcoming catalysts. The next is the IMCIVREE® (setmelanotide) topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | RHYTHM PHARMACEUTICALS, INC. |
| Ticker | RYTM (Nasdaq) |
| SEC CIK | 1649904 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rytm |

## Cash runway

Cash $320.9M as of 2026-09-30; quarterly burn $3.1M; about 314.4 months of runway at that rate (XBRL company facts, accession 0001628280-26-069485).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 25, 2020 | [IMCIVREE® (setmelanotide) FDA approval](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, approved | "NDA213793 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201125, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22)) |
| Jun 2022 | [IMCIVREE® (setmelanotide) FDA approval](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, approved | "FDA approved IMCIVREE for BBS in June 2022" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d2.htm)) |
| June 16, 2022 | [IMCIVREE® (setmelanotide) label expansion decision](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, approved | "NDA213793 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name RHYTHM; product IMCIVREE (SETMELANOTIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213793%22)) |
| December 20, 2024 | [IMCIVREE® (setmelanotide) label expansion decision](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, approved | "On December 20, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for IMCIVREE to include children as young as 2 years old with syndromic or monogenic obesity due to BBS or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm)) |
| Q1 2025 | [IMCIVREE® (setmelanotide) trial start](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | scheduled | "The Company plans to initiate a new, 26-week, open-label Phase 2 trial evaluating setmelanotide for treatment of Prader-Willi Syndrom ("PWS") in the first quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm)) |
| Q1 2025 | [RM-718 trial start](https://sec-api.dev/pdufa/rm-718) | RYTM | acquired hypothalamic obesity | scheduled | "With RM-718, we anticipate initiating Part C of our Phase 1 trial to evaluate this weekly MC4R agonist in patients with acquired hypothalamic obesity in the first quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm)) |
| January 10, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "The Company plans to report its fourth quarter and full year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d1.htm)) |
| February 26, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226xex99d1.htm)) |
| Q2 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity - | scheduled | ""Our global trial of setmelanotide in patients with acquired hypothalamic obesity - which is on track for topline data readout in the second quarter of 2025 - is being conducted in North America, Europe and Japan, and this reacquisition of rights for China, Hong Kong and Macau means Rhythm now owns the global franchise." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025003374/rytm-20250314xex99d1.htm)) |
| April 7, 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, positive | "BOSTON, April 7, 2025 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm)) |
| April 7, 2025 | [IMCIVREE® (setmelanotide) trial start](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed | "On April 7, 2025, Rhythm announced it dosed the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial of setmelanotide." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm)) |
| May 7, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm)) |
| Q3 2025 | [RM-718 topline data readout](https://sec-api.dev/pdufa/rm-718) | RYTM | acquired hypothalamic obesity | scheduled | "We anticipate reading out topline data from our Phase 2 trial evaluating bivamelagon in patients with acquired hypothalamic obesity in the third quarter of 2025, and we anticipate completing enrollment in Part C of the Phase 1 trial evaluating the weekly RM-718 in patients with acquired hypothalamic obesity." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006765/rytm-20250331x10q.htm)) |
| Q3 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | scheduled | ""Following compelling topline results from our pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO), we look forward to completing U.S. and EU regulatory submissions in the third quarter of 2025 and, pending approval, bringing the first-ever known approved therapy for this serious disease to patients," said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm)) |
| July 9, 2025 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM |  | completed, positive | "(Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/tm2520203d1_ex99-1.htm)) |
| August 5, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/rytm-20250805xex99d1.htm)) |
| August 20, 2025 | [IMCIVREE® (setmelanotide) NDA/BLA acceptance](https://sec-api.dev/pdufa/setmelanotide) | RYTM | conditions associated with acquired hypothalamic obesity | completed | "On August 20, 2025, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted for filing the Company's sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| November 4, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| December 11, 2025 | [IMCIVREE® (setmelanotide) interim data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, positive | "On December 11, 2025, we announced positive interim results from our exploratory Phase 2 trial of setmelanotide in patients with PWS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030549/rytm-20260331.htm)) |
| December 11, 2025 | [RM-718 trial start](https://sec-api.dev/pdufa/rm-718) | RYTM |  | completed | "•On December 11, 2025, the Company announced that it has initiated a Part D arm in the Phase 1/2 trial of MC4R agonist RM-718 that will enroll up to 20 patients with PWS; and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| December 19, 2025 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity; Genetic Obesity | completed | "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05093634)) |
| December 20, 2025 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | delayed | "-- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| January 9, 2026 | [IMCIVREE® (setmelanotide) earnings report](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed | "® 4 Continued Growth in IMCIVREE Global Sales ~10% increase in number of patients globally on reimbursed therapy 11% Q4 2025 preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) QoQ increase from Q3 2025** 68% of Q4 2025 revenue from U.S. 69% of FY 2025 revenue from U.S. $57M* Q4 2025 ~ $194M FY 2025 ~ The Company plans to report fourth quarter and full year 2025 financial results in February * Preliminary, unaudited Q4 2025 revenue from vials shipped to U.S. specialty pharma in excess of vials dispensed to patients is approximately $1.7M; **Reminder: During Q3 2025, Rhythm recorded a one-time $3.2 million charge following a final agreement with French authorities for reimbursement for IMCIVREE for POMC/LEPR and BBS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit992rytm_january20.htm)) |
| February 9, 2026 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443)) |
| February 26, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| Mar 2026 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | scheduled | "A supplemental cohort of 12 Japanese patients remains ongoing with completion and topline data anticipated in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm)) |
| Mar 2026 | [RHYTHM PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | scheduled | "We expect to read out topline results for these data from this Japanese cohort in March 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm)) |
| Mar 2026 | [RHYTHM PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | scheduled | "EMANATE, our pivotal Phase 3 program comprised of four independent substudies across genetically defined MC4R-pathway diseases, is expected to deliver topline results from each substudy in March 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm)) |
| March 19, 2026 | [IMCIVREE® (setmelanotide) FDA approval](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired HO | completed, approved | "•On March 19, 2026, the Company announced IMCIVREE was approved by the FDA for the treatment of acquired HO;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm)) |
| March 19, 2026 | [IMCIVREE® (setmelanotide) label expansion decision](https://sec-api.dev/pdufa/setmelanotide) | RYTM | living with acquired hypothalamic obesity | completed, approved | "On March 19, 2026, Rhythm Pharmaceuticals, Inc. ("Rhythm") issued a press release and published a presentation announcing that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO), which is summarized under Item 8.01 below." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm)) |
| March 20, 2026 | [RM-718 PDUFA date](https://sec-api.dev/pdufa/rm-718) | RYTM |  | scheduled | "Next-generation assets *Pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026; **pending regulatory feedback" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/ex992rytm20260313emanate.htm)) |
| March 20, 2026 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, approved | "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm)) |
| May 5, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm)) |
| June 24, 2026 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | "NCT06596135 (Open-Label Extension Study of Setmelanotide): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-24 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06596135)) |
| August 4, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/q22026earningspr_draft.htm)) |
| late 2026 | [Bivamelagon trial start](https://sec-api.dev/pdufa/bivamelagon) | RYTM | hypothalamic obesity | scheduled | "Following a highly constructive end-of-phase-2 meeting with the FDA where we shared encouraging open-label extension data focused on our oral MC4R agonist bivamelagon, we remain on track to initiate a Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| October 30, 2026 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | completed | "NCT06046443 (A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-10-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046443?tab=results)) |
| November 3, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026069106/q32026earningspr.htm)) |
| November 3, 2026 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Prader-Willi Syndrome; Obesity; Hyperphagia | completed | "NCT06772597 (A Study of Setmelanotide in Patients With Prader-Willi Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-03 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06772597)) |
| Nov 2026 to Feb 2027 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Prader-Willi Syndrome; Obesity; Hyperphagia | scheduled | "NCT06772597 (A Study of Setmelanotide in Patients With Prader-Willi Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-03 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06772597)) |
| November 12, 2026 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity; Genetic Obesity | completed | "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05093634?tab=results)) |
| Mar to Jun 2027 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | scheduled | "NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-13 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760546)) |
| March 2027 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | scheduled | "NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-13 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760546)) |
| Apr to Jul 2028 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | scheduled | "NCT07156578 (A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-04-15 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156578)) |
| April 2028 | [Bivamelagon primary completion](https://sec-api.dev/pdufa/bivamelagon) | RYTM | Hypothalamic Obesity | scheduled | "NCT07156578 (A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-04-15 (ESTIMATED); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156578)) |

## Drugs

- [Bivamelagon](https://sec-api.dev/pdufa/bivamelagon): hypothalamic obesity, hypothalamic obesity in 2026, acquired hypothalamic obesity
- [RM-718](https://sec-api.dev/pdufa/rm-718): acquired hypothalamic obesity
- [IMCIVREE® (setmelanotide)](https://sec-api.dev/pdufa/setmelanotide): acquired hypothalamic obesity, acquired ho, living with acquired hypothalamic obesity, conditions associated with hypothalamic obesity, conditions associated with acquired hypothalamic obesity, acquired hypothalamic obesity -, Hypothalamic Obesity, Obesity

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rytm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RYTM catalysts: RHYTHM PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rytm/catalysts

```bibtex
@misc{secapidev_companies_rytm_catalysts_20261116,
  title        = {RYTM catalysts: RHYTHM PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rytm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rytm_catalysts_20261116","title":"RYTM catalysts: RHYTHM PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rytm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
